Wedbush Raises Ardelyx Price Target to $19 Amid Outperform Rating
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6d ago
0mins
Source: Benzinga
- Ardelyx Price Target Raised: Wedbush increased Ardelyx Inc (NASDAQ:ARDX) price target from $16 to $19 while maintaining an Outperform rating, indicating confidence in the company's growth prospects.
- Southern Copper Rating Downgraded: UBS raised the price target for Southern Copper Corp (NYSE:SCCO) from $143 to $148 but downgraded the stock from Neutral to Sell, reflecting concerns about its short-term performance.
- Waste Management Price Target Cut: Scotiabank lowered the price target for Waste Management Inc (NYSE:WM) from $254 to $250, with analyst Konark Gupta downgrading the stock from Sector Outperform to Sector Perform, suggesting caution regarding future growth.
- Carter's Price Target Increased: Citigroup raised the price target for Carter’s Inc (NYSE:CRI) from $34 to $50 and upgraded the stock from Neutral to Buy, indicating a positive outlook on its market performance.
Analyst Views on ARDX
Wall Street analysts forecast ARDX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ARDX is 14.33 USD with a low forecast of 10.00 USD and a high forecast of 19.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 7.800
Low
10.00
Averages
14.33
High
19.00
Current: 7.800
Low
10.00
Averages
14.33
High
19.00
About ARDX
Ardelyx, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing first-in-class medicines. The Company has two commercial products approved in the United States: IBSRELA (tenapanor) and XPHOZAH (tenapanor). IBSRELA is a first-in-class NHE3 inhibitor approved by the United States FDA for the treatment of irritable bowel syndrome with constipation in adults. XPHOZAH is a first-in-class phosphate absorption inhibitor approved in the United States to reduce serum phosphorus in adults with chronic kidney disease (CKD) on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy. It has agreements for the development and commercialization of tenapanor outside of the United States. Kyowa Kirin commercializes PHOZEVEL (tenapanor) for hyperphosphatemia in Japan. A New Drug Application for tenapanor for hyperphosphatemia has been approved in China with Fosun Pharma.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
